Physician profile
Michael C Mcclay
NPI 1881669802
$2,737.42
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,421 · 2020: $155 · 2021: $725 · 2022: $437.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $566.53 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $306.92 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $250.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $240.51 | 2019 | |
| Alcon Vision LLC | $228.06 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $169.20 | 2019 | |
| Maculogix, INC. | $126.34 | 2021 | |
| Bausch & Lomb Americas INC. | $125.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $124.94 | 2022 | |
| Sight Sciences, INC. | $124.67 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $124.02 | 2021 | |
| Coopervision INC. | $113.88 | 2019 | |
| Optos, INC. | $101.97 | 2019 | |
| Alcon Research LLC | $85.38 | 2019 | |
| Shire North American Group INC | $50.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcclay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.